Integrating best practices in AI, genomics, cell culture, and laboratory techniques together contribute to protein expression success.

First chikungunya vaccine approved in Europe for persons as young as 12 years old. On track for launch in key European ...

Hyderabad: Biological E. Limited has announced a strategic partnership with Bavarian Nordic A/S to expand access to Bavarian ...

First chikungunya vaccine approved in Europe for persons as young as 12 years old.On track for launch in key European markets in the first half of 2025. COPENHAGEN, Denmark, February 28, 2025 ...

The global mammalian transient protein expression market is on a robust growth trajectory, projected to reach USD 762.34 million in 2024 and expand at a CAGR of 5.5% over the next decade, ultimately ...

Paul Chaplin, President and CEO of Bavarian Nordic said, "We are pleased to announce our first collaboration to expand global access to our Chikungunya Vaccine and also our first partnership with ...

The World Health Organization (WHO) today announced the recommendations for the viral composition of influenza vaccines for ...

The microbial fermentation technology market is experiencing significant growth, fueled by the increasing incidence of chronic diseases like cancer a ...

D. Boral Capital reaffirmed their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a research report released on Friday,Benzinga reports. The firm currently has a $30.00 target price ...

The ChAdOx1 viral vector was developed at the University of Oxford and has been investigated as a potential vector for ...

ImmunityBio, Inc.’s IBRX share price has surged by 15.03%, which has investors questioning if this is right time to sell.

The India cell culture media bags market is on a strong growth trajectory, projected to reach USD 35.7 million by 2025, with a compound annual growth rate (CAGR) of 5.6%, pushing its valuation beyond ...